Navigation Links
New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema

NEWPORT NEWS, Va., and SAN DIEGO, Dec. 2 /PRNewswire/ -- The Patient Advocate Foundation (PAF), with support from ImpediMed Ltd. (ASX: IPD), is pleased to announce the launch of the Lymphedema CareLine (LCL). PAF, through its MedCare Division, is offering the national, toll-free patient/provider hotline designed to provide information and assistance to breast cancer patients who are or may be at risk for post-treatment side effects such as lymphedema (swelling due to blockage in the lymphatic system).

Staffed by a dedicated team of multilingual clinical case managers with nursing and social work experience, the LCL offers personal case management services, including the dissemination of information about lymphedema, navigation through the reimbursement system, interpretation of a patients' health insurance benefit language, provision of direct appeals assistance and linkage to appropriate educational and support resources. The hotline can be accessed at (866) 949-1978 or on the Web at

The LCL is the latest addition to PAF's portfolio of patient services, which include direct case management services; the National Hispanic/Latino, African American and Senior Outreach initiatives; Hematologic Cancer Education Program; ACS/PAF Partnership Program and the national Lance Armstrong Foundation Livestrong SurvivorCare partnership.

"While better treatment and earlier detection of breast cancer has extended survival rates, lymphedema remains a significant risk to a woman's quality of life," said John Ennis, Co-Founder, Chief Development Officer at PAF. "We are encouraged to know that ImpediMed's technology can aid doctors in the pre-operative clinical assessment and ongoing surveillance of patients to help manage this impairment in newly diagnosed breast cancer patients and women at risk."

Beth Darnley, Chief Program Officer at PAF, added, "Navigating the reimbursement system in order to obtain appropriate pre- and post-operative care following a diagnosis of breast cancer can be confusing and overwhelming for patients. Options such as the Lymphedema CareLine offer a centralized resource for information and direct support to help clinicians and their patients manage this potentially serious side effect of primary breast cancer treatment."

Greg Brown, ImpediMed's CEO, commented: "ImpediMed is proud to support PAF's Lymphedema CareLine. Patients and doctors can be guided to available resources that help put lymphedema education and counseling on the clinical care agenda from day one. ImpediMed's FDA-cleared device is designed to aid doctors in the clinical assessment of patients for any signs of lymphedema when it is most likely to be effectively treated."

About Lymphedema

Lymphedema is a condition that can cause significant swelling of the upper and lower extremities due to the build-up of excess lymph fluid. This can occur when the lymphatic system, which is responsible for draining excess fluid from the body and is a key component of the immune system, is damaged or altered. In breast cancer patients, this can occur after surgery, such as removal or biopsy of the lymph nodes, and/or radiation therapy. It is estimated that 6 percent to 40 percent of patients with breast cancer develop lymphedema, and that it often occurs within the first two years after surgery. For some cancer survivors and others at risk, lymphedema can occur 10 years to 15 years following the initial primary treatment and develop into a condition that has a serious impact on overall health and quality of life.

About Patient Advocate Foundation

Patient Advocate Foundation is a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability.

More information may be obtained at or by calling (800) 532-5274.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies to aid medical providers in the non-invasive clinical assessment and ongoing surveillance of lymphedema. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists to clinically assess patients for the potential onset of secondary lymphedema. Pre-operative clinical assessment in breast cancer survivors before the onset of symptoms may help prevent the condition from becoming a lifelong management issue and improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary lymphedema of the arm in female breast cancer patients. For more information, visit or

    Contact Patient Advocate Foundation:
    Beth Darnley, Chief Program Officer
    (757) 952-1365 or (800) 532-5274
    Contact ImpediMed:
    Jack Butler, VP Business Development
    (585) 248-2554 or (877) 247-0111

SOURCE ImpediMed Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine
2. KGI Entrepreneur Program Hosts Angel Investing Educational Meeting
3. Varian, Inc. CEO to Speak at the Nasdaq OMX 22nd Investor Program
4. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
5. Cascades Technologies, Inc. Chosen to Deliver IT Support on a DoD Blast Injury Research Program
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
8. Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs
9. Dorset County Hospital Enhances MRSA Surveillance Programme Through Rapid Patient Screening
10. Rapidly Expanding Ohio Bioscience Industry Drives New Workforce Training Program
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Post Your Comments:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... CALIFORNIA (PRWEB) , ... October 10, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation for ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness ... targeting the needs of consumers who are incorporating medical marijuana into their wellness ... Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s two ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):